Active Ingredient(s): Amivantamab-vmjw
FDA Approved: * May 21, 2021
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

Amivantamab, sold under the brand name Rybrevant, is a bispecific antibody medication used to treat non-small cell lung cancer.[1][2][3] The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood test... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Rybrevant 350 mg Intravenous Injection
NDC: 57894-501
Janssen Biotech, Inc.